Long-term outcomes and dynamics of mutants associated with lamivudine-adefovir rescue therapy in patients with lamivudine-resistant chronic hepatitis B.
Abstract: The population of rtM204 mutants persisted or increased in 8 of 12 patients, and rtA181T mutants newly emerged as a minor population in four patients until 96 weeks.
Result: However, none of these four patients who developed the rtA181T mutation showed virological breakthrough during 96 weeks of LAM-ADV combination therapy.
Result: LAM-resistant (rtL180M and rtM204I/V) and ADV-resistant (rtA181V/T and rtN236T) mutation profiles were followed through RFMP assay at weeks 48 and 96 of the combination therapy.
[Clinical emergence features and implications of hepatitis B virus rtA181T mutation].
Abstract: CONCLUSION: The HBV rtA181T mutation is closely associated with adefovir and lamivudine exposure.rtA181T may led to sW172*, culminating in suppression of HBsAg secretion.However, co-existence of the mutant with wild-type sequences was common among our patient population, suggesting that the mutation had little impact on serum HBsAg and HBV DNA levels across the clinical study population.
Abstract: METHODS: Serum samples from 3, 013 patients who visited The 302 Hospital (Beijing, China) were investigated.HBV DNA was extracted and HBV mutations and genotypes were determined by direct sequencing.Recombinant plasmids harboring the rtA181T/
Microarray-based genotyping and detection of drug-resistant HBV mutations from 620 Chinese patients with chronic HBV infection.
PMID: 25982306
2015
The Brazilian journal of infectious diseases
Abstract: Of these, nine and eight patients carried lamivudine (LAM)-/telbivudine (LdT)-resistance mutations (rtL180M, rtM204I/V) and adefovir (ADV)-resistance mutations (rtA181T/V, rtN236T), respectively.
Delayed Reduction of Hepatitis B Viral Load and Dynamics of Adefovir-Resistant Variants during Adefovir plus Entecavir Combination Rescue Therapy.
PMID: 26005376
2015
International journal of medical sciences
Introduction: They include rtA181V/T and rtN236T.
Introduction: This may be attributed to an ADV-resistant variant, rtA181V/T, which is responsible for cross-resistance to LAM and ADV.
Discussion: This is mainly attributed to the ADV mutation, rtA181V/T, which is responsible for cross-resistance to LAM and ADV.
Detection and analysis of resistance mutations of hepatitis B virus.
PMID: 26309637
2015
International journal of clinical and experimental medicine
Abstract: L180M, M204I and M204V were associated with the resistance to lamivudine and telbivudine; L180M, M204I, M204V and V173L were associated with the resistance to entecavir; A181T, N236T and N/H238T were related to the resistance to adefovir.
Epidemiology study of HBV genotypes and antiviral drug resistance in multi-ethnic regions from Western China.
Abstract: Genotype C isolates had higher rates of rtA181T/V than genotype B .
Introduction: As a multi-drug resistant mutation, rtA181T/V has cross-resistance to LMV, LdT and TDF as well.
Result: As shown in Table 2, ADV-associated mutation rtA181V/T/S demonstrated a remarkable higher prevalence in genotype C than genotype B (13.5% vs.
Result: Interestingly, cross-resistant mutation rate of rtA181V/T/S was higher in patients harboring genotype C than genotype B in LMV-resistant patients (29.3% vs.
Result: The rate of other drug-associated resistant mutation models, such as rtA181T
Efficacy of tenofovir disoproxil fumarate therapy in nucleoside-analogue naive Iranian patients treated for chronic hepatitis B.
Result: No patient harbored previously described amino acid substitutions, including substitutions that could be associated with reduced TDF susceptibility (rtA181V/T, rtN236T or rtA194T).
Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy.
Result: 1C, Supplementary Table S2), neither rtA181T nor rtM204I was found at a frequency >=1% in any of the subjects at baseline measurement.
Result: A theoretical analysis based on the above simulation showed that relatively low packaging efficiency (delta <= 0.5) prevents rtA181T mutants from achieving dominance when coexisting with the wild-type quasispecies, in accord with the observed frequencies of rtA181T mutants (1.7 ~ 10.6%) in the viral populations of PVR patients (Supplementary Table S2).
Result: Although the rtM204I mutant was not detected at any of the time points from baseline to VB in patient VB.3, the
A novel pyridazinone derivative inhibits hepatitis B virus replication by inducing genome-free capsid formation.
PMID: 26349829
2015
Antimicrobial agents and chemotherapy
Abstract: Both the 3TC/ETV dually resistant L180M/M204I mutant and the adefovir (ADV)-resistant A181T/N236T mutant were as susceptible to 3711 as wild-type HBV.
HBV mutation literature information.
PMID: 
2015
Antiviral therapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT